Investing in 0—>1(Idea—>IP)
Drug Discovery
Viva Ventures Biotech Fund: Accessing $2 Trillion Global Pharmaceutical Market
VIVA VENTURE BIOTECH FUND
Viva Ventures Biotech Fund leverages 24 scientific GP partners to invest in 0->1 (idea to pre-clinical, first-in-class) drug discovery startups. The fund uses a peer-to-peer review method and selects 12-15 startups from 600+ deals reviewed per year. Viva Ventures targets blockbuster or billion dollar-sales new drug/ distributive innovative biotech startups with a success rate of over 60%, potential 3 X annual return, over 2-3 years investment period.
FUND PORTFOLIO
For more details about Viva Ventures Biotech Fund, please visit: www.VivaVenturesBiotech.com,
or send an inquiry to Xiliu@vivaventuresbiotech.com.
OTHER INVESTMENT
CHINA FUNDS
Huaxing Capital
CYZone Fund
Shunwei Capital
Huasheng Fund
Lightspeed China
Quantitative Strategy Fund
GLOBAL FUNDS
Dyal II
Stepstone co-investment fund
Amino Capital
OTHER DIRECT INVESTMENT
Kickback
Funplus
Stripe
Wanda IPO
Alibaba IPO
Expert Partners
Interest-aligned, 10-year partnering with global veteran drug hunters
Investor Relationship
18 years experience in providing financial services to near 1000 investors
Risk Control
20 years experience in investment risk control
TEAM
Global Capital Allocation
20 years experience in first-tier investment banks in London, Hongkong and Beijing
TEAM
CONTACT US
We look forward to new talents joining us or business collaboration. Please feel free to send your inquiry to services@jmcrpartners.com.
